<DOC>
	<DOCNO>NCT02750592</DOCNO>
	<brief_summary>Assess clinical efficacy , safety tolerability secukinumab subcutaneous injection 52 week Japanese patient active AS despite current previous non-steroidal anti-inflammatory drug ( NSAIDs ) and/or anti-tumor necrosis factor ( TNF ) α therapy . Efficacy safety data use support registration secukinumab Japan treatment active AS .</brief_summary>
	<brief_title>Study Efficacy Safety Secukinumab Japanese Patients With Active Ankylosing Spondylitis</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Diagnosis moderate severe AS prior document radiologic evidence ( xray radiologist 's report ) fulfil Modified New York criterion AS active AS assessed BASDAI ≥ 4 ( 010 ) spinal pain measure VAS≥ 4 cm ( BASDAI question # 2 ) Baseline Patients NSAIDs high recommend dose least 3 month prior baseline inadequate response failure respond , less 3 month therapy withdrawn due intolerance , toxicity contraindication Patients TNFα inhibitor ( one ) must experience inadequate response previous current treatment give approve dose least 3 month prior baseline intolerant least one administration antiTNFα agent Patients total ankylosis spine Patients previously treat biological immunomodulating agent except target TNFα Active ongoing inflammatory disease AS might confound evaluation benefit secukinumab therapy , include inflammatory bowel disease uveitis Known infection HIV , hepatitis B hepatitis C screening baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Ankylosing Spondylitis</keyword>
</DOC>